Oncology clinical trials regulations & benefits
Upcoming SlideShare
Loading in...5
×
 

Oncology clinical trials regulations & benefits

on

  • 277 views

A brief awareness presentation about Oncology Clinical Trials and how the current regulatory scenario is affecting it. The oncology patients are the greatest losers.

A brief awareness presentation about Oncology Clinical Trials and how the current regulatory scenario is affecting it. The oncology patients are the greatest losers.

Statistics

Views

Total Views
277
Views on SlideShare
277
Embed Views
0

Actions

Likes
0
Downloads
1
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Oncology clinical trials regulations & benefits Oncology clinical trials regulations & benefits Presentation Transcript

    • 1 Oncology Clinical Trials- Regulations & Benefits Dr.Harsha Doddihal Associate Medical Director Quintiles Disclaimer: The views expressed here are in personal capacity and do not represent that of Quintiles.
    • 2 Objective • Understanding Regulatory Scenario in India • How this affects Oncology community and patients • Brief Mention about Oncology Phase 1 and 2 trials • Remarkable Story! • Disclosure: Apart from being an Oncophysician, I also work as Associate Medical Director at Quintiles an have the responsibility of working with pharmaceutical companies, advising them on clinical research.
    • 3 Need For Regulations • Moral & Ethical Challenges International: 1. Nuremberg Code 2. Tuskegee Syphilis Experiments 3. Beecher Article in NEJM 1966 4. Belmont Report 5. ICH-GCP 1990 http://www.hhs.gov/ohrp/archive/documents/BeecherArticle.pdf http://www.wemos.nl/files/Documenten%20Informatief/Bestanden%20voor%20'Medicijnen'/examples_of_unethical_trials_feb_2008.pdf http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1121689/ National: 1. Letrozole Trial For Ovulation-2004 2. Streptokinase Trial-2003, 8 deaths 3. John Hopkins Scientist & RCC Trivandrum-26 oral cancer pts 4. HPV Vaccine Trial-Khammam district 5. Indore Story Image Courtesy http://crfocus.wordpress.com/tag/clinical-trials/
    • 4
    • 5 Regulations Today • In the case of an injury occurring to the clinical trial subject, he or she shall be given free medical management as long as required. • Financial compensation above that of medical management • Failure of investigational product to provide intended therapeutic effect will be considered as trial related injury. • Injury or death resulting due to placebo in a placebo controlled trial will be considered as trial related and will require compensation. • Adverse effects due to concomitant medication excluding standard care, necessitated as part of approved protocol; • Drugs and Cosmetics (First Amendment) Rules, 2013
    • 6 Impact On Oncology 39,767 studies listed on clinical trial site of US 526 studies listed on clinical trial site of India No trials approved this year!
    • 7 Why Does It Matter? • Patients are the greatest sufferers, being denied the chance, hope of research therapy and paving way for future • Personalized medicine demands need for local trials. Era of extrapolating data will gradually change • Lack of bio banks and local epidemiology, pathology data • Academic studies have come to a halt • Students facing problem in doing thesis • WHO, NIH funded trials have been withdrawn or stalled • MNCs and Indian companies are doing trials in other countries
    • 8 Phase 1 and Phase 2 in Oncology • Phase 1 trials in Oncology are done in patients suffering from malignancy. In other therapeutic areas phase 1 is done on healthy volunteers. • Phase 2 Oncology trials can be randomized and accelerated to provide both safety, efficacy results. • Personalized Medicine requires more innovative thinking. We need better trial designs, adaptive trials etc.
    • 9 An Inspiring Story • An example…. At age 44 (1992) diagnosed of CML- Started on Hydroxyurea- only short duration response She received Busulphan-Not effective Started on Interferon-alpha while being considered for Bone Marrow 1994- For Autologous BMT Stem cells were harvested at St Vincents Australia With Interferon she did well and was on it from 1994 to 2000 2000- Decided to participate in Imatinib trial at Singapore She went into accelerated phase on Imatinib in 2002 and received 3 cycles of chemotherapy and received Imatinib again 2005- The resistance to Imatinib was full blown and she was found to have T315I mutation. She also developed Parkinson in 2005 She did not fit for the Nilotinib trial in 2005 MK0457 a pahse1/2 trial for T315I mutation, they could not participate because of logistic reasons Imatinib dose increase did not help and she was put back on interferon, after 9 months she deteriorated New trial of inject able drug called Omacetaxine- side effects of losing teeth, skin- the intensity decreased For 2 years she was on Omacetaxine before moving to a new trail involving Ponatinib She is doing well on Ponatinib
    • 10 An Inspiring Story • An example…. At age 44 (1992) diagnosed of CML- Started on Hydroxyurea- only short duration response She received Busulphan-Not effective Started on Interferon-alpha while being considered for Bone Marrow 1994- For Autologous BMT Stem cells were harvested at St Vincents Australia With Interferon she did well and was on it from 1994 to 2000 2000- Decided to participate in Imatinib trial at Singapore She went into accelerated phase on Imatinib in 2002 and received 3 cycles of chemotherapy and received Imatinib again 2005- The resistance to Imatinib was full blown and she was found to have T315I mutation. She also developed Parkinson in 2005 She did not fit for the Nilotinib trial in 2005 MK0457 a pahse1/2 trial for T315I mutation, they could not participate because of logistic reasons Imatinib dose increase did not help and she was put back on interferon, after 9 months she deteriorated New trial of inject able drug called Omacetaxine- side effects of losing teeth, skin- the intensity decreased For 2 years she was on Omacetaxine before moving to a new trial involving Ponatinib She is doing well on Ponatinib
    • 11 • What can you do about it? > Being aware helps patients, physician and society! > Ignorance harms. Being aware of ethical concerns empowers and enhances. Allows one to ensure adherence of guidelines and SOPs > CDSCO invites people to comment on new rules and regulations!! We need to log on to their site and provide our comments. > Currently comments are being accepted for taking informed consent under video. Thank You!! Questions???? Curates Egg………Something good, something bad…….